Regeneron Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema ...

Nemluvio, which was also approved for prurigo nodularis, becomes Galderma’s first approved biologic in its dermatology ...

(Reuters) - Regeneron Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema treatment, Dupixent, and announced a dividend and stock buyback ...

(Reuters) - Regeneron Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema treatment, Dupixent, and announced a dividend and stock buyback ...

Sanofi’s Dupixent has shown there is a market for biologic drugs to treat eczema, and now Spain’s Almirall wants a piece of the action. The company’s head of external innovation and ...

This can cause the immune response that leads to eczema symptoms. Some specific problems with a part of the immune system called the adaptive immune system probably also contribute to the disease.